Anzeige
Mehr »
Freitag, 31.10.2025 - Börsentäglich über 12.000 News
Weltweiter Kaliboom treibt Nachfrage - ACM positioniert sich im 93,5 Mrd. USD-Markt bis 2032!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40WEG | ISIN: KYG0411D1236 | Ticker-Symbol:
NASDAQ
30.10.25 | 18:21
11,300 US-Dollar
-19,92 % -2,810
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
APOLLOMICS INC Chart 1 Jahr
5-Tage-Chart
APOLLOMICS INC 5-Tage-Chart

Aktuelle News zur APOLLOMICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
APOLLOMICS Aktie jetzt für 0€ handeln
15.10.Apollomics Inc.: Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation109FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) ("Apollomics" or the "Company"), a California based late-stage clinical biopharmaceutical company developing multiple...
► Artikel lesen
14.10.Nasdaq, Inc.: Nasdaq Resumes Trading in Apollomics Inc.3
14.10.Apollomics Inc. - 6-K, Report of foreign issuer1
14.10.Apollomics Inc.: Apollomics, Inc. Company Operational Continuity Update74FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) ("Apollomics" or the "Company"), today announced the following company operational update. Apollomics is a clinical-stage...
► Artikel lesen
25.09.Apollomics Inc. - 6-K, Report of foreign issuer13
17.09.Nasdaq, Inc.: Nasdaq Halts Apollomics Inc., Ltd.13
05.09.Apollomics Inc. - 6-K, Report of foreign issuer1
28.08.Apollomics Inc. - 6-K, Report of foreign issuer2
25.07.Apollomics Inc. - 6-K, Report of foreign issuer1
03.04.Apollomics Inc.: Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress254Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor ("EGFRi") to bring in $10 million upfront payment and expand dataset to combination therapyNew...
► Artikel lesen
20.12.24Apollomics Inc.: Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia302FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology...
► Artikel lesen
10.12.24Apollomics Inc.: Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement152FOSTER CITY, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat...
► Artikel lesen
21.11.24Apollomics Inc.: Apollomics' Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split339FOSTER CITY, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology...
► Artikel lesen
13 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1